Lantheus announces corporate plans, CAD agent strategy

03/24/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said it is undertaking measures to cut costs, including decreasing internal research and development and obtaining a partner for the final development of its PET radiopharmaceutical for diagnosing coronary artery disease, 18F-flurpiridaz. The partner will help with the remainder of Phase III development and commercialization, Lantheus said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN